Rheumatology Doctors in Davis, CA Accepting Medicare

6 Rheumatology doctors found. Showing 1 - 6

Stanley Masaji Naguwa, M.D. Internal Medicine - Rheumatology Medicare: Medicare Enrolled Practice Location: 2660 W Covell Blvd, Suite A, Davis, CA 95616 Phone: 530-747-3074    Fax: 530-792-8556

James Castles, M.D. Internal Medicine - Rheumatology Medicare: Not Enrolled in Medicare Practice Location: 451 E. Health Sciences Drive, Suite 6510, Davis, CA 95616 Phone: 530-752-2884    Fax: 530-754-6047

Dr. Gurtej Cheema, M.D. Internal Medicine - Rheumatology Medicare: Accepting Medicare Assignments Practice Location: 451 E. Health Sciences Drive, Suite 6510, Davis, CA 95616 Phone: 530-752-2884    Fax: 530-754-6047

Happy Chan, Internal Medicine - Rheumatology Medicare: Not Enrolled in Medicare Practice Location: 451 E Health Sciences Drive Gbsf Suite 6510, Division Of Rheumatology, Davis, CA 95616 Phone: 530-752-2884

Dr. Merrill E Gershwin, Internal Medicine - Rheumatology Medicare: Accepting Medicare Assignments Practice Location: 451 E. Health Sciences Drive, Davis, CA 95616 Phone: 530-752-2884    Fax: 530-752-4669

Dr. Dick L. Robbins, MD Internal Medicine - Rheumatology Medicare: Not Enrolled in Medicare Practice Location: 451 E. Health Sciences Drive, Ucdavis School Of Medicine, Davis, CA 95616 Phone: 530-752-3903    Fax: 530-754-6047

News Archive

Afghanistan facing challenges in effort to eradicate polio by end of 2012

"Afghanistan is intensifying efforts to eradicate polio by the end of next year, but security remains a major challenge especially in the southern provinces where the virus is localized, says" Arshad Quddus, head of the WHO polio program in Afghanistan, IRIN reports.

ZymoGenetics commences Phase 2B study of PEG-Interferon lambda in hepatitis C

ZymoGenetics, Inc. today announced the initiation of the second part of a Phase 2 clinical trial with PEG-Interferon lambda (IL-29) and ribavirin in treatment-naïve patients with chronic hepatitis C virus (HCV) infection. ZymoGenetics is developing the investigational compound PEG-Interferon lambda in collaboration with Bristol-Myers Squibb Company.

Waters to present MassTrak solutions at American Association of Clinical Chemistry annual meeting

Waters Corporation is showcasing its portfolio of MassTrak solutions at the American Association of Clinical Chemistry annual meeting and Clinical Lab Expo July 25 - 29, 2010 in Anaheim in exhibit booth #4447. Waters portfolio of MassTrak Solutions for the clinical laboratory combines the power of separations science, tandem mass spectrometry, specialized chemistries, software, and support services in ways designed to optimize laboratory processes.

Cardiac myosin-binding protein C identified as potential new diagnostic biomarker for heart attacks

Though they remain a leading killer, heart attacks can be effectively treated provided they can be rapidly diagnosed following initial onset of symptoms. In a study appearing in this month's Molecular and Cellular Proteomics, researchers have identified cardiac myosin-binding protein C (cMyBP-C) as a potential new diagnostic biomarker for heart attacks, one that may be particularly valuable for mild attacks in which traditional diagnostic proteins may not be abundant enough.

Read more Medical News

› Verified 7 days ago